Pfizer's Xalkori conditionally approved in Europe for previously treated lung cancer
This article was originally published in Scrip
Executive Summary
The European Commission has granted conditional marketing authorisation to Pfizer's Xalkori (crizotinib) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) and followed the recommendation of the EU CHMP, restricting the use of the drug to previously treated adults.